Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor

Andrea Fernandez Coves; Mirre Scholte; Jonathan Emerson; Robert Wolff; Teebah Abu-Zahra; Jiongyu Chen; Kevin McDermott; Nigel Armstrong; Manuela Joore; Willem Witlox

doi:10.1007/s40273-026-01592-6

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor

Andrea Fernandez Coves
, Mirre Scholte
, Jonathan Emerson
, Robert Wolff
, Teebah Abu-Zahra
, Jiongyu Chen
, Kevin McDermott
, Nigel Armstrong
, Manuela Joore
, Willem Witlox^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Number of pages	4
Journal	Pharmacoeconomics
DOIs	https://doi.org/10.1007/s40273-026-01592-6
Publication status	E-pub ahead of print - 1 Feb 2026

Keywords

ONCOLOGY

Access to Document

10.1007/s40273-026-01592-6

Cite this

Coves, A. F., Scholte, M., Emerson, J., Wolff, R., Abu-Zahra, T., Chen, J., McDermott, K., Armstrong, N., Joore, M., & Witlox, W. (2026). Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor. Pharmacoeconomics. Advance online publication. https://doi.org/10.1007/s40273-026-01592-6

Coves, Andrea Fernandez ; Scholte, Mirre ; Emerson, Jonathan et al. / Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations : Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor. In: Pharmacoeconomics. 2026.

@article{ce97a27c65134c0695b06e10561da721,

title = "Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor",

keywords = "ONCOLOGY",

author = "Coves, \{Andrea Fernandez\} and Mirre Scholte and Jonathan Emerson and Robert Wolff and Teebah Abu-Zahra and Jiongyu Chen and Kevin McDermott and Nigel Armstrong and Manuela Joore and Willem Witlox",

year = "2026",

month = feb,

day = "1",

doi = "10.1007/s40273-026-01592-6",

language = "English",

journal = "Pharmacoeconomics",

issn = "1170-7690",

publisher = "Adis",

}

Coves, AF, Scholte, M, Emerson, J, Wolff, R, Abu-Zahra, T, Chen, J, McDermott, K, Armstrong, N, Joore, M & Witlox, W 2026, 'Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor', Pharmacoeconomics. https://doi.org/10.1007/s40273-026-01592-6

Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor. / Coves, Andrea Fernandez; Scholte, Mirre; Emerson, Jonathan et al.
In: Pharmacoeconomics, 01.02.2026.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations

T2 - Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor

AU - Coves, Andrea Fernandez

AU - Scholte, Mirre

AU - Emerson, Jonathan

AU - Wolff, Robert

AU - Abu-Zahra, Teebah

AU - Chen, Jiongyu

AU - McDermott, Kevin

AU - Armstrong, Nigel

AU - Joore, Manuela

AU - Witlox, Willem

PY - 2026/2/1

Y1 - 2026/2/1

KW - ONCOLOGY

U2 - 10.1007/s40273-026-01592-6

DO - 10.1007/s40273-026-01592-6

M3 - Comment/Letter to the editor

SN - 1170-7690

JO - Pharmacoeconomics

JF - Pharmacoeconomics

ER -

Coves AF, Scholte M, Emerson J, Wolff R, Abu-Zahra T, Chen J et al. Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor. Pharmacoeconomics. 2026 Feb 1. Epub 2026 Feb 1. doi: 10.1007/s40273-026-01592-6